CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+5.68%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$4.78B
AUM Growth
–
Cap. Flow
+$4.74B
Cap. Flow
% of AUM
99.08%
Top 10 Holdings %
Top 10 Hldgs %
14.27%
Holding
616
New
605
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
CELG
Celgene Corp
CELG
|
+$84.5M |
| 2 |
Gilead Sciences
GILD
|
+$83.7M |
| 3 |
Apple
AAPL
|
+$79.3M |
| 4 |
Qualcomm
QCOM
|
+$74.7M |
| 5 |
Amgen
AMGN
|
+$73M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 24.38% |
| 2 | Financials | 14.02% |
| 3 | Technology | 12.71% |
| 4 | Industrials | 8% |
| 5 | Energy | 6.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
United Therapeutics
UTHR
$18B
| $3.76M | 0.08% |
+29,000
| New | +$3.76M |
|
|
ACHN
277
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $3.74M | 0.08% |
+305,000
| New | +$3.74M |
|
|
GEVA
278
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $3.71M | 0.08% |
+40,000
| New | +$3.71M |
|
|
HES
279
DELISTED
Hess
HES
| $3.69M | 0.08% |
+50,018
| New | +$3.69M |
|
280
United Rentals
URI
$60.9B
| $3.66M | 0.08% |
+35,828
| New | +$3.66M |
|
281
Canadian National Railway
CNI
$57.9B
| $3.63M | 0.08% |
+52,532
| New | +$3.63M |
|
|
BHI
282
DELISTED
Baker Hughes
BHI
| $3.6M | 0.08% |
+64,191
| New | +$3.6M |
|
|
TWX
283
DELISTED
Time Warner Inc
TWX
| $3.52M | 0.07% |
+41,169
| New | +$3.52M |
|
284
SBA Communications
SBAC
$20.9B
| $3.44M | 0.07% |
+31,097
| New | +$3.44M |
|
285
Becton Dickinson
BDX
$54B
| $3.44M | 0.07% |
+25,301
| New | +$3.44M |
|
286
Insmed
INSM
$30.6B
| $3.4M | 0.07% |
+220,000
| New | +$3.4M |
|
287
TJX Companies
TJX
$155B
| $3.33M | 0.07% |
+97,068
| New | +$3.33M |
|
288
Target
TGT
$41.2B
| $3.3M | 0.07% |
+43,404
| New | +$3.3M |
|
|
AVDL
289
Avadel Pharmaceuticals
AVDL
$1.55B
| $3.29M | 0.07% |
+192,000
| New | +$3.29M |
|
290
Canadian Natural Resources
CNQ
$64.7B
| $3.27M | 0.07% |
+218,232
| New | +$3.27M |
|
|
RGLS
291
DELISTED
Regulus Therapeutics
RGLS
| $3.21M | 0.07% |
+1,667
| New | +$3.21M |
|
292
Alnylam Pharmaceuticals
ALNY
$61.2B
| $3.2M | 0.07% |
+33,000
| New | +$3.2M |
|
293
Pacira BioSciences
PCRX
$1.19B
| $3.19M | 0.07% |
+36,000
| New | +$3.19M |
|
|
EIGR
294
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.13M | 0.07% |
+356
| New | +$3.13M |
|
295
Franklin Resources
BEN
$12.6B
| $3.1M | 0.06% |
+56,051
| New | +$3.1M |
|
296
BioCryst Pharmaceuticals
BCRX
$1.69B
| $3.08M | 0.06% |
+253,000
| New | +$3.08M |
|
297
Danaher
DHR
$139B
| $3.02M | 0.06% |
+52,381
| New | +$3.02M |
|
298
Stryker
SYK
$146B
| $3.01M | 0.06% |
+31,956
| New | +$3.01M |
|
299
Automatic Data Processing
ADP
$118B
| $3M | 0.06% |
+36,025
| New | +$3M |
|
|
IMMU
300
DELISTED
Immunomedics Inc
IMMU
| $3M | 0.06% |
+625,000
| New | +$3M |
|